HRP20230623T1 - Polipeptidi koji sadrže fc domenu s promijenjenom glikozilacijom i smanjenom efektorskom funkcijom - Google Patents
Polipeptidi koji sadrže fc domenu s promijenjenom glikozilacijom i smanjenom efektorskom funkcijom Download PDFInfo
- Publication number
- HRP20230623T1 HRP20230623T1 HRP20230623TT HRP20230623T HRP20230623T1 HR P20230623 T1 HRP20230623 T1 HR P20230623T1 HR P20230623T T HRP20230623T T HR P20230623TT HR P20230623 T HRP20230623 T HR P20230623T HR P20230623 T1 HRP20230623 T1 HR P20230623T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody according
- image
- residue
- glycan
- antibody
- Prior art date
Links
- 239000012636 effector Substances 0.000 title claims 7
- 230000013595 glycosylation Effects 0.000 title 1
- 238000006206 glycosylation reaction Methods 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 150000004676 glycans Chemical group 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 235000001014 amino acid Nutrition 0.000 claims 4
- 150000001720 carbohydrates Chemical group 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims 3
- 239000002619 cytotoxin Substances 0.000 claims 3
- 125000005647 linker group Chemical group 0.000 claims 3
- 101710112752 Cytotoxin Proteins 0.000 claims 2
- 125000003172 aldehyde group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 239000000611 antibody drug conjugate Substances 0.000 claims 2
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229930182830 galactose Chemical group 0.000 claims 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 150000002923 oximes Chemical class 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims 1
- 125000005629 sialic acid group Chemical group 0.000 claims 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2012/003819 WO2013037484A2 (en) | 2011-09-12 | 2012-09-12 | Anti-aplhabetatcr antibody |
| US201361776715P | 2013-03-11 | 2013-03-11 | |
| EP18166377.4A EP3366705B1 (en) | 2012-09-12 | 2013-09-12 | Fc containing polypeptides with altered glycosylation and reduced effector function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230623T1 true HRP20230623T1 (hr) | 2023-09-29 |
Family
ID=50278674
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230623TT HRP20230623T1 (hr) | 2012-09-12 | 2013-09-12 | Polipeptidi koji sadrže fc domenu s promijenjenom glikozilacijom i smanjenom efektorskom funkcijom |
| HRP20181354TT HRP20181354T1 (hr) | 2012-09-12 | 2013-09-12 | Polipeptidi koji sadrže fc s izmjenjenom glikozilacijom i smanjenom efektorskom funkcijom |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20181354TT HRP20181354T1 (hr) | 2012-09-12 | 2013-09-12 | Polipeptidi koji sadrže fc s izmjenjenom glikozilacijom i smanjenom efektorskom funkcijom |
Country Status (34)
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
| US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
| IL319584A (en) | 2013-03-11 | 2025-05-01 | Genzyme Corp | Polypeptides with hyperglycosidic bonds |
| CN116333148A (zh) * | 2014-03-19 | 2023-06-27 | 建新公司 | 靶向模块的位点特异性糖工程化 |
| US10905678B2 (en) | 2014-04-08 | 2021-02-02 | University Of Georgia Research Foundation, Inc. | Site-specific antibody-drug glycoconjugates and methods |
| KR102451080B1 (ko) * | 2014-06-12 | 2022-10-06 | 씨에스피씨 메가리스 바이오파마슈티칼 씨오., 엘티디. | 효소적 방법을 통한 균일한 항체 약물 접합체 |
| PT3204425T (pt) | 2014-10-09 | 2020-12-18 | Genzyme Corp | Conjugados anticorpo fármaco glicomanipulados |
| TW202417497A (zh) | 2015-10-12 | 2024-05-01 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| EP3222292A1 (en) | 2016-03-03 | 2017-09-27 | Heidelberg Pharma GmbH | Amanitin conjugates |
| TW201815821A (zh) | 2016-07-18 | 2018-05-01 | 美商再生元醫藥公司 | 抗茲卡病毒抗體及使用方法 |
| JP7042816B2 (ja) | 2016-11-08 | 2022-03-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | レプチン受容体をアンタゴナイズする抗原結合性タンパク質 |
| WO2018107116A1 (en) * | 2016-12-09 | 2018-06-14 | Abbvie Stemcentrx Llc | Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby |
| GB201717446D0 (en) | 2017-10-24 | 2017-12-06 | Evox Therapeutics Ltd | Affinity purification of engineering extracellular vesicles |
| KR20200100089A (ko) | 2017-12-18 | 2020-08-25 | 리제너론 파마슈티칼스 인코포레이티드 | 렙틴 수용체 및/또는 gp130에 결합하는 이중 특이적 항원 결합 분자 및 이의 사용 방법 |
| SI3773713T1 (sl) | 2018-04-06 | 2025-08-29 | Regeneron Pharmaceuticals, Inc. | Protitelo, agonist leptinskega receptorja, za uporabo pri povečanju kostne mase pri osebi, ki trpi zaradi presnovne disfunkcije ali hipoleptinemije |
| JP1640846S (enExample) * | 2018-10-16 | 2019-09-09 | ||
| KR20210093856A (ko) | 2018-11-21 | 2021-07-28 | 리제너론 파마슈티칼스 인코포레이티드 | 항-스타필로코쿠스 항체 및 이의 사용 |
| AU2019403404B2 (en) | 2018-12-21 | 2025-05-29 | Regeneron Pharmaceuticals, Inc. | Rifamycin analogs and antibody-drug conjugates thereof |
| AU2020214812B2 (en) | 2019-02-01 | 2025-10-02 | Regeneron Pharmaceuticals, Inc. | Anti-IL2 receptor gamma antigen-binding proteins |
| AU2020248645A1 (en) * | 2019-03-27 | 2021-10-28 | Tigatx, Inc. | Engineered IgA antibodies and methods of use |
| MA55529A (fr) | 2019-04-03 | 2022-02-09 | Genzyme Corp | Polypeptides de liaison anti-alpha bêta tcr à fragmentation réduite |
| CA3182893A1 (en) | 2020-05-08 | 2021-11-11 | Regeneron Pharmaceuticals, Inc. | Vegf traps and mini-traps and methods for treating ocular disorders and cancer |
| CN116670170A (zh) | 2020-09-15 | 2023-08-29 | 瑞泽恩制药公司 | Lepr激动剂用于疼痛的用途 |
| KR20220052098A (ko) | 2020-10-20 | 2022-04-27 | 주식회사 엘지에너지솔루션 | 마스킹 테이프를 이용한 전극 시편에 대한 물성 측정 시스템 및 이를 이용한 물성 측정 방법 |
| KR102576252B1 (ko) * | 2021-04-07 | 2023-09-11 | 아주대학교산학협력단 | 산화된 면역글로불린을 유효성분으로 포함하는 면역조절 기능 이상 관련 질환 예방 또는 치료용 약학적 조성물 |
| US20240408408A1 (en) * | 2021-10-22 | 2024-12-12 | Trustees Of Tufts College | Fap-targeted neutron capture agents, and uses and formulations related thereto |
| KR20250058123A (ko) | 2022-07-29 | 2025-04-29 | 리제너론 파마슈티칼스 인코포레이티드 | 항-TfR:페이로드 융합 및 이의 사용 방법 |
| MA71631A (fr) | 2022-07-29 | 2025-05-30 | Regeneron Pharmaceuticals, Inc. | Particules virales reciblées vers le récepteur 1 de transferrine |
| WO2024026474A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle |
| IL320016A (en) | 2022-11-04 | 2025-06-01 | Regeneron Pharma | Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle |
| KR20250120451A (ko) | 2022-11-14 | 2025-08-08 | 리제너론 파마슈티칼스 인코포레이티드 | 항-fgfr3 항체 및 항원 결합 단편 및 이의 사용 방법 |
| US20240173426A1 (en) | 2022-11-14 | 2024-05-30 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes |
| WO2024259206A1 (en) | 2023-06-16 | 2024-12-19 | Regeneron Pharmaceuticals, Inc. | Cd40 x cd40 bispecific antigen-binding molecules and uses thereof |
| TW202519551A (zh) | 2023-07-28 | 2025-05-16 | 美商雷傑納榮製藥公司 | 用於治療酸性神經髓磷脂酶缺乏症之抗ＴｆＲ：酸性神經髓磷脂酶 |
| WO2025029657A2 (en) | 2023-07-28 | 2025-02-06 | Regeneron Pharmaceuticals, Inc. | Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease |
| TW202535925A (zh) | 2023-10-25 | 2025-09-16 | 比利時商艾伯霖克斯公司 | 具有增強的Ｆｃ受體結合之Ｆｃ結構域變體 |
| WO2025099632A1 (en) | 2023-11-08 | 2025-05-15 | Sanofi | Cd25 based lysosomal degrader and uses thereof |
| WO2025160340A2 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration |
| TW202540428A (zh) | 2024-01-26 | 2025-10-16 | 美商雷傑納榮製藥公司 | 使用漿細胞耗乏劑及／或ｂ細胞耗乏劑遏制宿主抗ａａｖ抗體反應且實現ａａｖ轉導及重複給藥的方法及組成物 |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| WO2025184603A2 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration |
| EP4616869A1 (en) * | 2024-03-15 | 2025-09-17 | Oncomatryx Biopharma, S.L. | Fap targeted antibody-drug conjugates |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
| US5837821A (en) | 1992-11-04 | 1998-11-17 | City Of Hope | Antibody construct |
| GB9422383D0 (en) | 1994-11-05 | 1995-01-04 | Wellcome Found | Antibodies |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5989830A (en) | 1995-10-16 | 1999-11-23 | Unilever Patent Holdings Bv | Bifunctional or bivalent antibody fragment analogue |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| EP0918872B1 (en) | 1996-08-02 | 2008-02-20 | Bristol-Myers Squibb Company | A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| ES2292236T3 (es) | 1998-04-02 | 2008-03-01 | Genentech, Inc. | Variantes de anticuerpos y sus fragmentos. |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| EP1006183A1 (en) | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
| EP2364997A3 (en) | 1999-01-15 | 2012-07-04 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP1294904A1 (en) | 2000-06-30 | 2003-03-26 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Heterodimeric fusion proteins |
| GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
| AU2002248184C1 (en) | 2000-12-12 | 2018-01-04 | Board Of Regents, The University Of Texas System | Molecules with extended half-lives, compositions and uses thereof |
| US6900292B2 (en) * | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
| US20040002587A1 (en) * | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| KR20040088572A (ko) | 2002-03-01 | 2004-10-16 | 이뮤노메딕스, 인코오포레이티드 | 제거율 증강을 위한 양특이성 항체 점 돌연변이들 |
| AU2003262650B2 (en) | 2002-08-14 | 2009-10-29 | Macrogenics, Inc. | FcgammaRIIB-specific antibodies and methods of use thereof |
| DK2364996T3 (en) | 2002-09-27 | 2017-02-06 | Xencor Inc | Optimized Fc variants and methods for their formation |
| AU2003286467B2 (en) | 2002-10-15 | 2009-10-01 | Abbvie Biotherapeutics Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| JP2006524039A (ja) | 2003-01-09 | 2006-10-26 | マクロジェニクス，インコーポレーテッド | 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法 |
| MXPA05013565A (es) * | 2003-06-12 | 2006-03-09 | Lilly Co Eli | Proteinas de fusion analogas al glp-1. |
| US8399618B2 (en) * | 2004-10-21 | 2013-03-19 | Xencor, Inc. | Immunoglobulin insertions, deletions, and substitutions |
| GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
| AU2004290070A1 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto |
| EP1697520A2 (en) | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
| KR101149242B1 (ko) | 2004-01-12 | 2012-05-25 | 어플라이드 몰리큘라 에볼류션, 인코포레이티드 | Ｆｃ 영역 변이체 |
| AU2005227326B2 (en) | 2004-03-24 | 2009-12-03 | Xencor, Inc. | Immunoglobulin variants outside the Fc region |
| WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2006085967A2 (en) | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
| SI2471813T1 (sl) | 2004-07-15 | 2015-03-31 | Xencor, Inc. | Optimirane Fc variante |
| US20060084145A1 (en) * | 2004-09-27 | 2006-04-20 | Anderson Glenn M | sRAGE mimetibody, compositions, methods and uses |
| WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
| JP2008537941A (ja) * | 2005-03-31 | 2008-10-02 | ゼンコー・インコーポレイテッド | 最適化特性を有するＦｃ変異体 |
| BRPI0611445A2 (pt) * | 2005-05-09 | 2010-09-08 | Glycart Biotechnology Ag | molécula de ligação a antìgeno glicomanipulada, polinucleotìdeo, polipeptìdeo, vetor, célula hospedeira, método para produção, uso e composição farmacêutica |
| US8163881B2 (en) | 2005-05-31 | 2012-04-24 | The Board Of Regents Of The University Of Texas System | Immunoglobulin molecules with improved characteristics |
| EP1896071B1 (en) | 2005-06-30 | 2015-04-29 | Janssen Biotech, Inc. | Methods and compositions with enhanced therapeutic activity |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US8460364B2 (en) | 2006-07-20 | 2013-06-11 | Orbusneich Medical, Inc. | Bioabsorbable polymeric medical device |
| JP5357778B2 (ja) * | 2007-01-23 | 2013-12-04 | ゼンコー・インコーポレイテッド | 最適化ｃｄ４０抗体および前記を使用する方法 |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| EP2444491B1 (en) * | 2008-04-21 | 2016-11-16 | Novo Nordisk Healthcare Ag | Hyperglycosylated human coagulation factor IX |
| KR20230005405A (ko) * | 2011-02-25 | 2023-01-09 | 추가이 세이야쿠 가부시키가이샤 | ＦｃγＲＩＩｂ 특이적 Ｆｃ 항체 |
| TWI671315B (zh) | 2011-03-28 | 2019-09-11 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| UY34317A (es) * | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
-
2013
- 2013-09-12 PE PE2015000327A patent/PE20150650A1/es active IP Right Grant
- 2013-09-12 NZ NZ705983A patent/NZ705983A/en unknown
- 2013-09-12 HU HUE18166377A patent/HUE062876T2/hu unknown
- 2013-09-12 PL PL18166377.4T patent/PL3366705T3/pl unknown
- 2013-09-12 SG SG11201501521TA patent/SG11201501521TA/en unknown
- 2013-09-12 PL PL13766833T patent/PL2895513T3/pl unknown
- 2013-09-12 RS RS20230536A patent/RS64317B1/sr unknown
- 2013-09-12 EA EA202091166A patent/EA202091166A1/ru unknown
- 2013-09-12 DK DK13766833.1T patent/DK2895513T3/en active
- 2013-09-12 MY MYPI2015000513A patent/MY170126A/en unknown
- 2013-09-12 CN CN201380058863.8A patent/CN104797601B/zh active Active
- 2013-09-12 LT LTEP18166377.4T patent/LT3366705T/lt unknown
- 2013-09-12 HR HRP20230623TT patent/HRP20230623T1/hr unknown
- 2013-09-12 KR KR1020157009038A patent/KR102185151B1/ko active Active
- 2013-09-12 AU AU2013315499A patent/AU2013315499B2/en active Active
- 2013-09-12 CN CN201910721123.7A patent/CN110590953A/zh active Pending
- 2013-09-12 EP EP13766833.1A patent/EP2895513B1/en active Active
- 2013-09-12 PT PT13766833T patent/PT2895513T/pt unknown
- 2013-09-12 SG SG10201701831VA patent/SG10201701831VA/en unknown
- 2013-09-12 PT PT181663774T patent/PT3366705T/pt unknown
- 2013-09-12 SI SI201332053T patent/SI3366705T1/sl unknown
- 2013-09-12 ES ES13766833.1T patent/ES2684549T3/es active Active
- 2013-09-12 EP EP18166377.4A patent/EP3366705B1/en active Active
- 2013-09-12 RS RS20180981A patent/RS57748B1/sr unknown
- 2013-09-12 HU HUE13766833A patent/HUE039337T2/hu unknown
- 2013-09-12 JP JP2015532046A patent/JP6438397B2/ja active Active
- 2013-09-12 HR HRP20181354TT patent/HRP20181354T1/hr unknown
- 2013-09-12 MA MA37949A patent/MA37949B1/fr unknown
- 2013-09-12 EA EA201590545A patent/EA035987B1/ru unknown
- 2013-09-12 ES ES18166377T patent/ES2950509T3/es active Active
- 2013-09-12 WO PCT/US2013/059481 patent/WO2014043361A1/en not_active Ceased
- 2013-09-12 FI FIEP18166377.4T patent/FI3366705T3/fi active
- 2013-09-12 CA CA2884762A patent/CA2884762C/en active Active
- 2013-09-12 KR KR1020207033737A patent/KR102426488B1/ko active Active
- 2013-09-12 MX MX2015003234A patent/MX366103B/es active IP Right Grant
- 2013-09-12 EP EP23164492.3A patent/EP4223783A3/en active Pending
- 2013-09-12 LT LTEP13766833.1T patent/LT2895513T/lt unknown
- 2013-09-12 KR KR1020227025572A patent/KR20220110855A/ko not_active Ceased
- 2013-09-12 SI SI201331144T patent/SI2895513T1/sl unknown
- 2013-09-12 DK DK18166377.4T patent/DK3366705T5/da active
- 2013-12-09 UA UAA201503410A patent/UA116995C2/uk unknown
-
2015
- 2015-03-02 ZA ZA2015/01417A patent/ZA201501417B/en unknown
- 2015-03-05 DO DO2015000050A patent/DOP2015000050A/es unknown
- 2015-03-06 TN TNP2015000085A patent/TN2015000085A1/fr unknown
- 2015-03-09 IL IL237640A patent/IL237640B/en active IP Right Grant
- 2015-03-11 CL CL2015000606A patent/CL2015000606A1/es unknown
- 2015-03-11 PH PH12015500528A patent/PH12015500528A1/en unknown
- 2015-03-12 MX MX2019007753A patent/MX2019007753A/es unknown
- 2015-03-19 CR CR20150147A patent/CR20150147A/es unknown
- 2015-04-10 EC ECIEPI201514133A patent/ECSP15014133A/es unknown
-
2018
- 2018-08-23 CY CY181100880T patent/CY1120909T1/el unknown
-
2019
- 2019-11-28 IL IL271027A patent/IL271027B/en active IP Right Grant
-
2020
- 2020-08-23 IL IL276866A patent/IL276866B/en unknown
-
2021
- 2021-09-29 IL IL286766A patent/IL286766A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230623T1 (hr) | Polipeptidi koji sadrže fc domenu s promijenjenom glikozilacijom i smanjenom efektorskom funkcijom | |
| JP2016512425A5 (enExample) | ||
| JP2015533490A5 (enExample) | ||
| RU2015143057A (ru) | Гипергликозилированные связывающие полипептиды | |
| HRP20220455T1 (hr) | Modificirane aminokiseline koje sadrže azid grupu | |
| HRP20180443T1 (hr) | Povezujuće domene usmjerene protiv gpcr-a: g proteinski kompleksi i njihove derivirane uporabe | |
| HRP20190475T1 (hr) | Antitijela koja sadrže ne-prirodne aminokiselinske ostatke specifične za mjesto, metode njihovog pripremanja i metode njihove primjene | |
| EA201370076A1 (ru) | Иммуноглобулины-переносчики и их применение | |
| HRP20240676T1 (hr) | Proteini domena skele na bazi fibronektina koji vezuju miostatin | |
| MX359217B (es) | Composiciones que contienen, métodos que involucran, y usos de derivados de dolastatina unidos a aminoácidos no naturales. | |
| SG195183A1 (en) | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives | |
| CA2871160C (en) | Agents for influenza neutralization | |
| BR112016014913A8 (pt) | anticorpo, ou um fragmento de ligação ao antígeno do mesmo, conjugado, ácido nucléico, vetor, célula hospedeira, composição farmacêutica, método de preparo de uma cadeia leve de um anticorpo ou fragmento de ligação ao antígeno e método de preparo de um conjugado | |
| HRP20192311T4 (hr) | Adam6 miševi | |
| IL222792A0 (en) | Method of coupling an oligosaccharide to a protein, oligosaccharide-protein conjugates, uses thereof and pharmaceutical compositions comprising the same | |
| HRP20150664T1 (hr) | Antikancerogeni fuzijski protein | |
| NZ713602A (en) | Method for refining protein including self-cutting cassette and use thereof | |
| WO2012091564A3 (en) | A cross linking polypeptide comprising an hexameric single chain antibody binding mhc-mage complex that induces apoptosis | |
| WO2011094765A3 (en) | A targeting signal for integrating proteins, peptides and biological molecules into bacterial microcompartments | |
| MY160435A (en) | A novel antiviral peptide against avian influenza virus h9n2 | |
| EP2476438A4 (en) | MEDICAMENT HAVING AN ANTIBODY COMPOSITION SPECIFIC TO THE HUMAN CC CHEMOKIN RECEPTOR 4 (CCR4) | |
| Mrázek et al. | Carbohydrate synthesis and biosynthesis technologies for cracking of the glycan code: Recent advances | |
| WO2013009739A3 (en) | Soluble treponema pallidum protein tp0453,tp0453-tp0326 fusion protein, and use in syphilis diagnosis | |
| WO2010135054A3 (en) | Mutations in a toll-like receptor motif in the ns4b of classical swine fever virus skin brescia influences virulence in swine | |
| WO2012031023A3 (en) | Treatment of inflammatory bowel diseases using a tripeptide |